HEMOSTASIOLOGICAL ASPECTS OF TUMOR GROWTH


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data available in the current literature on the pathogenetic features of the interaction of the hemostatic system during tumor growth. Materials and methods. The review included the data of foreign and Russian papers published in the past 15 years and found in e-Library and Pubmed on this topic. Results. The paper describes the pathogenetic mechanisms responsible for the involvement of tissue factor in the process of tumor growth as the most significant tumor procoagulant. A separate section is devoted to the pathophysiology of tumor neoangiogenesis. The role of endothelial activation in the process of tumor growth is revealed in detail. Conclusion. The pathophysiological features of tumor growth make cancer perhaps the best example of acquired thrombophilia. A better understanding of the pathophysiology of thrombophilia in cancer should provide clinicians with a more accurate rationale for more aggressive and certain antithrombotic treatment strategies in patients with malignant tumors.

Full Text

Restricted Access

About the authors

Alexander D. Makatsaria

I.M. Sechenov First Moscow State Medical University

Email: gemostasis@mail.ru
Corresponding Member of Russian Academy of Sciences, Professor, MD, Head of the Department of Obstetrics and Gynecology, Faculty of Preventive Medicine Moscow 109004, Trubetskaya str. 8, bld. 2, Rissia

Alexander V. Vorobyev

I.M. Sechenov First Moscow State Medical University

Email: alvorobev@gmail.com
PhD, Associate Professor, Department of Obstetrics and Gynecology, Faculty of Preventive Medicine Moscow 109004, Trubetskaya str. 8, bld. 2, Rissia

References

  1. Buller H.R., van Doormaal F.F., van Sluis G.L., Kamphuisen P.W. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J. Thromb. Haemost. 2007; 5(Suppl. 1): 246-54.
  2. Varki A. Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110(6): 1723-9.
  3. Falanga A. Biological and clinical aspects of anticancer effects of antithrombotics. Pathophysiol. Haemost. Thromb. 2003-2004; 33(5-6): 389-92.
  4. Dammacco F., Vacca A., Procaccio P., Ria R., Marech I., Racanelli V. Cancer-related coagulopathy (Trousseau’s syndrome): review of the literature and experience of a single center of internal medicine. Clin. Exp. Med. 2013; 13(2): 85-97.
  5. Langer F., Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hämostaseologie. 2012; 32(2): 95-104.
  6. Ay C., Dunkler D., Pirker R., Thaler J., Quehenberger P., Wagner O. et al. High D-dimer level sare associated with poor prognosis in cancer patients. Haematologica. 2012; 97(8): 1158-64.
  7. Wang J.G., Geddings J.E., Aleman M.M., Cardenas J.C., Chantrathammachart P., Williams J.C. et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012; 119(23): 5543-52.
  8. Khorana A.A., Ahrendt S.A., Ryan C.K., Francis C.W., Hruban R.H., Hu Y.C. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res. 2007; 13(10): 2870-5.
  9. Uno K., Homma S., Satoh T., Nakanishi K., Abe D., Matsumoto K. et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br. J. Cancer. 2007; 96(2): 290-5.
  10. Davila M., Amirkhosravi A., Coll E., Desai H., Robles L., Colon J. et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J. Thromb. Haemost. 2008; 6(9): 1517-24.
  11. Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы. Монография. М.: Триада-Х; 2008. 650с
  12. Geddings J.E., Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013; 122(11): 1873-80.
  13. Lo L., Valentine H., Harrison J., Hayes S., Welch I., Pritchard S. et al. Tissue factor expression in the metaplasia-adenoma-carcinoma sequence of gastric cancer in a European population. Br. J. Cancer. 2012; 107(7): 1125-30.
  14. Van den Berg Y.W., Versteeg H.H. Alternatively spliced tissue factor. A crippled protein in coagulation or a key player in non-haemostatic processes? Hämostaseologie. 2010; 30(3): 144-9.
  15. Rak J., Yu J.L., Luyendyk J., Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res. 2006; 66(22): 10643-6.
  16. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. USA. 2001; 98(6): 3352-7.
  17. Bharthuar A., Khorana A.A., Hutson A., Wang J.G., Key N.S., Mackman N., Iyer R. V. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb. Res. 2013; 132(2): 180-4.
  18. Mackman N. New insights into the mechanisms of venous thrombosis. J. Clin. Invest. 2012; 122(7): 2331-6.
  19. Vorobiev A.V., Makatsaria A.D., Chabrov A.M. Thrombophilia markers in cancer patients during chemotherapy and radiation therapy. Pathophysiol. Haemost. Thromb. 2006; 35(1-2): A20.
  20. Kazmierczak M., Lewandowski K., Wojtukiewicz M.Z., Turowiecka Z., Kokacz E., Lojko A. et al. Cancer procoagulant in patients with adenocarcinomas. Blood Coagul. Fibrinolysis. 2005; 16(8): 543-7.
  21. Goldin-Lang P., Tran Q.V., Fichtner I., Eisenreich A., Antoniak S., Schulze K. et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol. Rep. 2008; 20(1): 123-8.
  22. Thaler J., Preusser M., Ay C., Kaider A., Marosi C., Zielinski C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb. Res. 2013; 131(2): 162-5.
  23. Thaler J., Ay C., Mackman N., Metz-Schimmerl S., Stift J., Kaider A. et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur. J. Clin. Invest. 2013; 43(3): 277-85.
  24. Ahlbrecht J., Dickmann B., Ay C., Dunkler D., Thaler J., Schmidinger M. et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J. Clin. Oncol. 2012; 30(31): 3870-5.
  25. Demers M., Wagner D.D. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin. Thromb. Hemost. 2014; 40(3): 277-83.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media